B lymphocyte

Japanese Journal of Clinical Immunology

Volumn 28, Issue 5, 2005, Pages 300-308

  Hasegawa, Minoru ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

autoimmune; B cell depletion; B lymphocyte; CD20; Rituximab

Indexed keywords

MONOCLONAL ANTIBODY; RITUXIMAB;

ANIMAL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; HUMAN; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MOUSE; PHYSIOLOGY; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; LYMPHOCYTE DEPLETION; MICE;

EID: 33644670533     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.28.300     Document Type: Article

References (28)

1. Martin F., Chan A.C.: Pathogenic roles of B cells in human autoimmunity, insights from the clinic. Immunity 20: 517–527, 2004.
2. Sato S., Fujimoto M., Hasegawa M., Takehara K., Tedder T.F.: Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 41: 1123–33, 2004.
3. Hasegawa M., Fujimoto M., Takehara K., Sato S.: Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibosis. J. Dermatol. Sci. 39: 1–7, 2005.
4. Tedder T. F., Inaoki M., Sato S.: The CD19/21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 6: 107–118, 1997.
5. Korganow A. S., Ji H., Mangialaio S., et al.: From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10: 451–461, 1999.
6. Matsumoto I., Staub A., Benoist C., Mathis D.: Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286: 1732–1735, 1999.
7. Matsumoto I., Maccioni M., Lee D. M., et al.: How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint- specific autoimmune disease. Nat. Immunol. 3: 360–365, 2002.
8. Chan O., Shlomchik M.J.: A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol 160: 51–59, 1998.
9. Chan O. T., Hannum L. G., Haberman A. M., Madaio M. P., Shlomchik MJ: A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 189: 1639–1648, 1999.
10. Saito E., Fujimoto M., Hasegawa M., et al.: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J. Clin. Invest. 109: 1453–1462, 2002.
11. Sato S., Fujimoto M., Hasegawa M., Takehara K.: Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 50: 1918–1927, 2004.
12. Sato S., Hasegawa M., Fujimoto M., Tedder T. F., Takehara K.: Quantitative genetic variation in CD19 expression correlates with autoimmunity. J. Immunol. 165: 6635–6643, 2000.
13. Leandro M. J., Edwards J. C., Cambridge G., Ehrenstein M. R., Isenberg D.A.: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46: 2673- 2677, 2002.
14. Cambridge G., Leandro M. J., Edwards J. C., et al.: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48: 2146–2154, 2003.
15. Edwards J. C., Cambridge G.: Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40: 205–211, 2001.
16. De Vita S., Zaja F., Sacco S., De Candia A., Fanin R., Ferraccioli G.: efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 46: 2029–2033, 2002.
17. Edwards J. C., Szczepanski L., Szechinski J., et al.: efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572–2581, 2004.
18. Edwards J. C., Leandro M.J.: B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. Curr Dir Autoimmun 8: 175–192, 2005.
19. Anolik J. H., Barnard J., Cappione A., et al.: Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50: 3580–3590, 2004.
20. Looney R. J., Anolik J. H., Campbell D., et al.: B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50: 2580–2589, 2004.
21. Albert D. A., Khan S. R., Stansberry J., Tsai D., Eisenberg R.A.: A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus. American College of Rheumatology Annual Meeting, 2003: Late Breaking Abstract 9.
22. Leandro M. J., Ehrenstein M. R., Edwards J. C., Mason J., Cambridge G., Isenberg D.A.: Treatment of refractory lupus nephritis with B lymphocyte depletion. Arthritis Rheum 48: S378, 2002.
23. Sfikakis P. P., Boletis J. N., Lionaki S., et al.: Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52: 501–513, 2005.
24. Tokunaga M., Fujii K., Saito K., et al.: Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 44: 176–182, 2004.
25. Zaja F., De Vita S., Mazzaro C., et al.: efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101:3827–3834, 2003.
26. Levine T.D.: Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52:601–607, 2005.
27. Uchida J., Hamaguchi Y., Oliver J. A., et al.: The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199: 1659–1669, 2004.
28. Hamaguchi Y., Uchida J., Cain D. W., et al.: The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol 174:4389–4399, 2005.